Skip to main content
Clinical Trials/JPRN-UMIN000001772
JPRN-UMIN000001772CompletedPhase 2

The clinical study on immunotherapy for advanced renal cell carcinoma =Combination therapy of natural IFN-alfa and meloxicam against metastatic renal cell crcinoma= - Combination therapy with meloxicam, a COX-2 inhibitor, and interferon alfa for metastatic renal cell carcinoma

Hokkaido Advanced Renal Cell Carcinoma Treatment Group0 sites50 target enrollmentStarted: March 13, 2009Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
50

Study Overview

Brief Summary

The combination of IFN-alfa and meloxicam is considered to be an effective therapy that achieves a higher response rate compared with that previously reported for IFN- monotherapy.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
15years-old to 85years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1. prior immunotherapy 2. Brain metastasis 3. Bone metastasis alone 4. active double cancers 5. Liver cirrhosis 6. uncontolled DM 7. Depression

Investigators

Sponsor
Hokkaido Advanced Renal Cell Carcinoma Treatment Group

Similar Trials